Newsstand Menu

Cancer cell’s “self eating” tactic may be its weakness

NIX protein PDAC Tuveson
Evidence of activity involving the NIX protein (brown staining) is seen in common precursor lesions (PanIN) for pancreatic cancer. NIX activity escalates in full pancreatic ductal adenocarcinoma (PDAC), the most common of pancreas cancers. NIX is directly responsible for triggering mitophagy, or “self eating” of mitochondria.

Cold Spring Harbor, NY — Cancer cells use a bizarre strategy to reproduce in a tumor’s low-energy environment; they mutilate their own mitochondria! Researchers at Cold Spring Harbor Laboratory (CSHL) also know how this occurs, offering a promising new target for pancreatic cancer therapies.

Why would a cancer cell want to destroy its own functioning mitochondria? “It may seem pretty counterintuitive,” admits M.D.-Ph.D. student Brinda Alagesan, a member of Dr. David Tuveson’s lab at CSHL.

According to Alagesan, the easiest way to think about why cancer cells may do this is to think of the mitochondria as a powerplant. “The mitochondria is the powerhouse of the cell,” she recites, recalling the common grade school lesson. And just like a traditional powerplant, the mitochondria create their own pollution.

“These harmful byproducts, or pollutants, are called reactive oxygen species, or ROS,” Alagesan adds. “A lot of it can be damaging to cells. We believe that [by eating their own mitochondria] the pancreatic cancer cells are reducing the production of these damaging ROS while still making enough energy to proliferate.”

This is still a hypothesis but it could explain why pancreatic cancer cells become prone to mitophagy, a form of autophagy or ‘self eating’ of their mitochondria.

In the journal Cancer Discovery, Alagesan and co-lead author Dr. Timothy Humpton describe what happens when a protein called KRAS becomes active in the uniquely nutrient-depleted environment of a pancreas tumor. KRAS starts a “signaling cascade” which results in the cell eating its own mitochondria and the diversion of glucose and glutamine away from the remaining mitochondria. These diverted nutrients are used to support cell division.

“Ideally, we would want to inhibit the cancer promoting KRAS protein directly, but unfortunately so far no one has been able to do that in a clinically relevant way,” Alagesan explains.

Instead of stopping KRAS directly, the Tuveson team traced the cascade of protein signals that follows KRAS activation. They found one pathway which leads to an increase in the protein NIX. NIX is directly responsible for triggering that mitophagy stage which appears to be so crucial for cancer cell proliferation.

“Results in mice are showing us that, by inhibiting the NIX pathway, we might prevent cancer cells from using energy the way they need to in order to proliferate,” Alagesan says.

The Tuveson team is now turning its attention to disrupting this same NIX pathway in human pancreatic cancer cells, and applying this to the design of clinical trials.

Written by: Brian Stallard, Content Developer/Communicator | bstallar@cshl.edu | 516-367-8455


Funding

This research was funded by the Lustgarten Foundation, Cold Spring Harbor Laboratory Association, the V Foundation, Cancer Research UK, the Gates Cambridge Trust, Cancer Research UK Programme and the National Institutes of Health.

Citation

Humpton, T. et. al, “Oncogenic Kras induces Nix-mediated mitophagy to promote pancreatic cancer” was published in Cancer Discovery on July 1, 2019.

Stayed informed

Sign up for our newsletter to get the latest discoveries, upcoming events, videos, podcasts, and a news roundup delivered straight to your inbox every month.

  Newsletter Signup

About Cold Spring Harbor Laboratory

Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,100 people including 600 scientists, students and technicians. The Meetings & Courses Program annually hosts more than 12,000 scientists. The Laboratory’s education arm also includes an academic publishing house, a graduate school and the DNA Learning Center with programs for middle and high school students and teachers. For more information, visit www.cshl.edu

Principal Investigator

David Tuveson

David Tuveson

Professor
Roy J. Zuckerberg Professor of Cancer Research
M.D., Ph.D., Johns Hopkins University, 1994

Tags